Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
A Rare Tumor That Fooled Doctors at Every Step — Until One Test Changed Everything
This case report and literature review describes a 64-year-old male with thoracic SMARCA4-deficient undifferentiated tumor initially misdiag…
A rare chest tumor mimicking lung cancer was misdiagnosed until a specific genetic test revealed the true cause, proving one marker can prev…
Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
AI Now Reads Tumor Slides Like a Radiologist — and Shows Its Work
This review/commentary outlines a Virtual Spectral Decomposition (VSD) methodological framework for analyzing digital pathology and imaging …
A new AI system reads cancer slides like a doctor and explains exactly which biological features drove each diagnosis.
Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
Why Your Lung Cancer Risk Is Not The Same As Your Neighbor's
This retrospective cohort study evaluated gene expression programs in early-stage (IA/IB) lung adenocarcinoma patients.
Hidden immune signals in early lung cancer act like a weather forecast, predicting who will stay well and who faces a quick return of the di…
NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
A Hidden Cell Type in Lung Cancer May Hold a New Target
This preclinical and computational study analyzed public databases and performed in vitro experiments to evaluate cancer-associated fibrobla…
A hidden protein in support cells around lung tumors may drive cancer growth, pointing to a new treatment target for lung adenocarcinoma.
Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
New Drug Combo Helps Some Lung Cancer Patients Live Longer
A single-arm, open-label phase Ib/II trial in 52 patients with pretreated stage IIIB/IV NSCLC adenocarcinoma found a 6-month progression-fre…
A new drug pair safely extends life for some advanced lung cancer patients who previously tried immunotherapy or have high PD-L1 markers.
Predictive nomogram with spectral CT radiomics and deep learning features improves preoperative STAS prediction in surgically resected lung adenocarcinoma
A Simple Scan May Now Predict a Hidden Lung Cancer Danger Before Surgery
This cohort study evaluated a predictive nomogram combining spectral dual-layer detector CT radiomics, deep learning features, and pleural i…
Doctors may soon use artificial intelligence to find a hidden sign of aggressive lung cancer before a patient ever goes into the operating r…
AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
A Simple Blood Test Could Predict Your Lung Cancer Treatment Success
This preprint describes an observational cohort study involving 1,720 lung adenocarcinoma patients, with validation across additional cohort…
A new blood test score predicts which lung cancer patients will respond to immunotherapy, helping doctors avoid ineffective treatments for a…
CT-based radiomics shows variable accuracy for predicting occult lymph node metastasis in early-stage lung adenocarcinoma
CT scan analysis shows promise for predicting hidden cancer spread in early lung cancer
A meta-analysis of 10 studies including 6,349 patients with early-stage lung adenocarcinoma found CT-based radiomics had pooled sensitivity …
Computer analysis of regular CT scans can spot hidden cancer spread in early lung cancer with about 85% accuracy when tested in the same hos…
Radiomics-ML model predicts invasiveness in subcentimeter subsolid lung adenocarcinoma
AI model shows promise for predicting cancer invasiveness in small lung nodules
A two-center retrospective cohort study of 260 patients with surgically confirmed subcentimeter subsolid lung adenocarcinoma developed and v…
An AI model predicts whether tiny, hazy lung spots are invasive cancer with 79% accuracy, offering a new tool for doctors to spot dangerous …
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
Gut Health Links May Influence Lung Cancer Treatment Paths
This narrative review with a systematic search examined 168 studies on the gut-lung axis in non-small-cell and small-cell lung cancer. Solub…
New research explores how the gut-lung axis and specific metabolites might play a role in managing lung cancer treatments.
Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Trial shows ivonescimab plus chemotherapy improves lung cancer outcomes
Ivonescimab plus pemetrexed and carboplatin significantly extends progression-free survival for patients with advanced EGFR-mutated NSCLC.
A new treatment combination involving ivonescimab and chemotherapy showed a significant improvement in progression-free survival for certain…
Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
Bispecific antibodies improve survival for patients with solid tumors
This meta-analysis of 3505 patients with solid tumors found that bispecific antibodies significantly improved progression-free survival (HR …
A new type of antibody treatment shows promise in extending life and slowing cancer growth for patients with solid tumors.
Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC
Adding chemotherapy to osimertinib extends survival for specific lung cancer
This Phase 3 randomized clinical trial of 294 treatment-naive, stage IV or recurrent nonsquamous NSCLC patients with concurrent TP53 and EGF…
A new combination of osimertinib and chemotherapy significantly extends the time patients with specific lung cancer mutations live without d…
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
Adding Chemotherapy to Immune Therapy for Lung Cancer Shows Mixed Results
A meta-analysis of 3,252 patients reveals that adding chemotherapy to ICI monotherapy does not provide a consistent survival advantage.
New analysis suggests that adding chemotherapy to immunotherapy for certain lung cancers may not provide a consistent survival benefit over …
EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
Combination therapies show promise for lung cancer with brain spread
This systematic review and network meta-analysis of 5432 patients with EGFR-mutated non-small cell lung cancer and brain metastases found th…
New data suggests that combining specific drugs can improve survival and slow cancer growth in patients with lung cancer that has spread to …
Robotic-assisted thoracoscopic segmentectomy results in lower intraoperative blood loss compared to video-assisted thoracoscopic segmentectomy
Robotic surgery shows less blood loss for early lung cancer
This meta-analysis of propensity-matched studies included 14,007 patients with early-stage non-small cell lung cancer undergoing segmentecto…
Robotic surgery may reduce blood loss during lung cancer procedures while providing similar survival rates to traditional methods.
Durvalumab plus tremelimumab shows no significant overall survival benefit compared to durvalumab alone
Adding tremelimumab to durvalumab does not improve lung cancer survival
This meta-analysis of 2726 patients with metastatic non-small cell lung cancer found no significant overall survival benefit for durvalumab …
Combining two specific immunotherapies for metastatic lung cancer does not improve survival but significantly increases the risk of severe s…
iPSC-derived CAR-NK extracellular vesicles represent a translational hypothesis for non-small cell lung cancer
New Research Explores Using Nanoscale Vesicles for Lung Cancer
This narrative review explores the use of iPSC-derived CAR-NK extracellular vesicles (EVs/sEVs) as an investigational platform for non-small…
Scientists are exploring how tiny vesicles from engineered cells might offer a safer way to deliver cancer treatments directly to lung tumor…
Metabolic parameters MTV and TLG predict poorer survival in NSCLC patients on immune checkpoint inhibitors
Specific PET scan metrics predict outcomes for lung cancer patients
This systematic review and meta-analysis of 33 studies evaluated baseline [18F] FDG PET/CT metabolic parameters as prognostic indicators for…
Certain measurements from PET scans can help doctors predict how well lung cancer patients will respond to immune checkpoint inhibitor thera…
Sunvozertinib improves progression-free survival in patients with advanced NSCLC and EGFR exon 20 mutations
New drug shows promise for specific type of lung cancer
This trial compared sunvozertinib against carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC featuring EGFR exon 20 inse…
A new drug called sunvozertinib may help patients with a specific lung cancer mutation live longer without their tumors growing.
Questions about Lung Adenocarcinoma
How does gene expression affect survival in early-stage lung adenocarcinoma?
Gene expression programs involving immune cells, stromal remodeling, and acylation modifications significantly predict survival and recurrence in early-stage lung adenocarcinoma.
Full answer →Can aumolertinib be used again after osimertinib causes lung problems?
Yes, aumolertinib (almonertinib) has been successfully used after osimertinib caused lung problems like interstitial lung disease, based on case reports.
Full answer →